Intraperitoneal Chemotherapy
The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma.
European Journal of Surgical Oncology 2019 March 23 [Link] Lurvink RJ, Villeneuve L, Govaerts K, de Hingh IHJT, Moran BJ, Deraco M, Van der Speeten K, Glehen O, Kepenekian V, Kusamura S Abstract Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and…
Read MoreCurrent status of cytoreductive surgery (CRS) and intraperitoneal hyperthermic chemotherapy (HIPEC) in the multimodal treatment of peritoneal surface malignancies.
Casopis Lekaru Ceskych 2019 Winter [Link] Klos D, Riško J, Stašek M, Loveček M, Hanuliak J, Skalický P, Lemstrová R, Mohelníková BD, Študentová H, Neoral Č, Melichar B. The tumors of the peritoneal surface, both primary and secondary, are associated with a very poor prognosis and rapid progression through conventional oncology treatment including systemic chemotherapy,…
Read MoreMalignant Peritoneal Mesothelioma: Treatment Options and Survival.
Anticancer Research 2019 February [Link] Salo SAS, Ilonen I, Laaksonen S, Myllärniemi M, Salo JA, Rantanen T Abstract BACKGROUND: Malignant peritoneal mesothelioma (MPeM) is a rare type of cancer with a poor prognosis. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) have been shown to improve survival. Treatment and survival of patients with MPeM have…
Read MoreWell-Differentiated Papillary Mesothelioma of the Peritoneum: A Retrospective Study from the RENAPE Observational Registry.
Annals of Surgical Oncology 2019 January 11 [Link] Vogin G1, Hettal L, Vignaud JM, Dartigues P, Goere D, Ferron G, Heyd B, Bereder JM, Tuech JJ, Glehen O, de Chaisemartin C, Lherm Y, Villeneuve L, Kepenekian V, Marchal F BACKGROUND: Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare entity. Questions regarding management are still being debated as no more than 50 cases have been reported in the literature. OBJECTIVE:…
Read MoreWell differentiated papillary peritoneal mesothelioma treated by cytoreduction and hyperthermic intraperitoneal chemotherapy-the experience of the PSOGI registry.
European Journal of Surgical Oncology 2018 October 19 [Link] Deraco M, Nizri E, Glehen O, Baratti D, Tuech JJ, Bereder JM, Kepenekian V, Kusamura S, Goere D Abstract BACKGROUND: Well differentiated papillary peritoneal mesothelioma (WDPPM) is a rare variant of mesothelioma which affects mainly women in the reproductive age. The disease may present multifocally and…
Read MoreUpdate on the management of malignant peritoneal mesothelioma.
Translational Lung Cancer Research 2018 October [Link] Sugarbaker PH Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease whose natural history is confined to the peritoneal space. Systemic chemotherapy has little impact on survival of patients with MPM. A surgical procedure with a goal of resection of all visible evidence of disease, called cytoreductive surgery…
Read MoreMalignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.
Annals of Gastroenterology 2018 Nov-Dec [Link] Boussios S, Moschetta M, Karathanasi A, Tsiouris AK, Kanellos FS, Tatsi K, Katsanos KH, Christodoulou DK Abstract Malignant peritoneal mesothelioma (MPM) is a rare disease with a wide clinical spectrum. It arises from the peritoneal lining and commonly presents with diffuse, extensive spread throughout the abdomen and, more rarely,…
Read MoreFirst case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.
BMC Medical Genetics 2018 August 15 [Link] Löffler MW, Steinhilber J, Hilke FJ, Haen SP, Bösmüller H, Montes-Mojarro IA, Bonzheim I, Stäbler A, Faust U, Grasshoff U, Königsrainer I, Rammensee HG, Kanz L, Königsrainer A, Beckert S, Riess O, Schroeder C Abstract BACKGROUND: The PTEN-hamartoma-tumor-syndrome (PHTS) is caused by germline mutations in Phosphatase and Tensin…
Read MoreDose-Dependent Effect of Red Blood Cells Transfusion on Perioperative and Long-Term Outcomes in Peritoneal Surface Malignancies Treated with Cytoreduction and HIPEC.
Annals of Surgical Oncology 2018 July 26 [Link] Nizri E, Kusamura S, Fallabrino G, Guaglio M, Baratti D, Deraco M Abstract BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are associated with increased red blood cell transfusion (RBT) demand. Although the deleterious effects of RBT are documented in various settings, its effect in this…
Read MoreImpact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Annals of Surgical Oncology 2018 July 5 [Link] Malgras B, Gayat E, Aoun O, Dico RL, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M Abstract BACKGROUND: The introduction of cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) improved the prognosis of…
Read More